OBJECTIVE To describe SLE disease activity patterns in the Hopkins Lupus Cohort. METHODS Disease activity was studied in 1886 patients followed-up for 1-28 years. Disease activity patterns were defined using (1) Physician Global Assessment (PGA) and (2) modified SLE Disease Activity Index (M-SLEDAI) as follows: long quiescent (LQ), M-SLEDAI=0/PGA=0 at all visits; relapsing-remitting (RR), per...

OBJECTIVES To examine SLEDAI-2000 cut-off scores for definition of active SLE and to determine the sensitivity to change of SLEDAI-2000 for the assessment of SLE disease activity and minimal clinically meaningful changes in score. METHODS Data from two multi-centre studies were used in the analysis: in a cross-sectional and a longitudinal fashion. At every assessment, data were collected on S...

background systemic lupus erythematosus (sle) is an autoimmune connective-tissue disease involving multiple organs and systems. some evidence has demonstrated that disease activity could be associated with increased risk of organ damage. objectives the aim of this study was to determine the association between systemic lupus erythematosus disease activity index (sledai) scores and subclinical c...

OBJECTIVE To assess the reliability of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2000 index in routine practice and its ability to capture disease activity as compared with the British Isles Lupus Assessment Group (BILAG)-2004 index. METHODS Patients with systemic lupus erythematosus from 11 centres were assessed separately by two raters in routine practice. Disease activit...

OBJECTIVE To characterize prognostic parameters for systemic lupus erythematosus (SLE) flares. METHODS In a prospective study, 120 SLE patients attending our out-patient clinic were evaluated every 3 months for 2 yr. At every visit clinical manifestations and laboratory parameters were assessed and the SLE disease activity index (SLEDAI) was determined. A correlation analysis of the number of...

Methods Serum level of GSTpi was quantified by immunoenzymatic method in 42 patients with active systemic lupus erythematous (based on SLEDAI score), without any treatment divided in two groups: Group A – 30 cases with active SLE (SLEDAI = 11.2 ± 3.2), with chronic C hepatitis; Group B – 12 cases with active SLE (SLEDAI = 12.1 ± 4.5) without hepatitis C. The results were compared to those obtai...

OBJECTIVE To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. METHODS Data obtained after 52 weeks of treatment from two phase III trials (BLISS-52 and BLISS-76) comparing belimumab 1 and 10 mg/kg versus placebo, plus standard therapy, in 1684 autoantibody-positive patients were analysed ...

Figure 3 is not correct in the published article. The correct Figure 3 is shown below. Figure 3: Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone usage. Each single cell forms a single row, and each column corresponds to an individual gene. All non-classical cells and genes are shown. Lower ...

Background Curcumin contained in Curcuma xanthorrhiza is an immunomodulator that has similar biological effect as vitamin D. Combination of curcumin and vitamin D3 is expected to work synergistically. Objective To determine the effect of Curcuma xanthorrhiza supplementation on vitamin D3 administration to SLEDAI, IL-6, and TGF-β1 serum in SLE patients with hypovitamin D. Methods This was a ...

OBJECTIVE The aim of this study was to develop an SLE disease model that simulates long-term outcomes of SLE to estimate the long-term effectiveness and cost-effectiveness of SLE treatments. METHODS Longitudinal data from 1354 patients from the Hopkins Lupus Cohort were included in the analysis. Statistical models were created to estimate disease activity [Safety of Estrogen in Lupus Erythema...